Treatment Of Maxillary Bone Cysts With Autologous Bone Mesenchymal Stem Cells (MSV-H)
This trial is active, not recruiting.
|Conditions||maxillary cyst, bone loss of substance|
|Treatment||autologous mesenchymal stem cells|
|Phase||phase 1/phase 2|
|Sponsor||Red de Terapia Celular|
|Collaborator||Sanidad de Castilla y Leon (SACYL)|
|Start date||April 2011|
|End date||May 2015|
|Trial size||10 participants|
|Trial identifier||NCT01389661, 2010-024246-30, BIOMAX-VA-2010, EC10-255, TerCel0002|
This trial pretends to validate for clinical use a bioengineered product composed of MSV cells (mesenchymal stem cells produced by IBGM, Valladolid, which have already been approved by the Spanish Regulatory Agency for three previous clinical trials) and a cross-linked matrix of autologous plasma patented by The Blood and Tissue Bank of Asturias (WO2008/ 119855) for bone maxillary cysts refilling. These two groups collaborate in the present project with the team of Maxillofacial Surgery of the Hospital Universitario del Río Hortega, who leads the clinical trial and deals with the medical aspects. The proposed trial is based on positive results obtained in previous animal studies performed by the present multidisciplinary team. The investigators propose a phase I / II clinical trial with 10 patients suffering from bone cysts in the maxillofacial region. Autologous mesenchymal stem cells isolated from a bone marrow sample will be seeded in the autologous plasma matrix and cultivated for 3 weeks. At this time, the cyst will be removed by surgery and the cavity filled with the protein matrix containing the mesenchymal cells. Checks will be conducted at 3 weeks, 3 and 6 months following the evolution of the cavity by panoramic radiography and computerized tomography scan.
|United States||No locations recruiting|
|Other countries||No locations recruiting|
|Valladolid, Spain||Río Hortega University Hospital||no longer recruiting|
|Malaga, Spain||Bionand, Parque Tecnológico de Andalucía, Universidad de Málaga||no longer recruiting|
|Valladolid, Spain||Instituto de Biologia y Genetica Molecular||no longer recruiting|
|Endpoint classification||safety/efficacy study|
|Intervention model||single group assignment|
To evaluate the feasibility and safety of the implementation of MSV in the treatment of maxillary cysts
time frame: up to 6 months
Indication of efficacy
time frame: up to 6 months
Male or female participants from 18 years up to 65 years old.
- Maxillar bone cyst with diameter larger than 2 cm and smaller than 4 cm
- Understanding and written acceptance of assay conditions
- Informed written consent of the patient for assay and for surgery
- In women, negative pregnancy test at t=0
- In women, compromise of using anticonceptive methods during the study
- Age under 18 or over 65
- Incapacity or legal dependence
- Pregnancy, lactancy, or enrollment in fertility programs
- Previous or concomitant oncological processes.
- Positive serology for HIV-1 orHIV-2, Hepatitis B (HBsAg, Anti-HCV-Ab) or Hepatitis C (Anti-HCV-Ab).
- Immunocompromised patients
- Systemic disease with potential effects on bone metabolism
- Congenital or acquired maxillofacial malformation
- Patients with prescription of drugs acting on bone metabolism, suc as glucocorticoids and bisphosphonates
- Active or recent infection of the cyst
- Recidive of the cyst (previous surgery)
- Participation in other trials or studies in the last 3 months.
- Other pathologic conditions or circumstances that difficult participation in the study according to medical criteria
|Official title||Regeneration of Maxillary Bone Cystic Cavities by Bio Implant of MSHV-H Cells Associated to a Cross-linked Serum Scaffold|
|Principal investigator||Luis M Redondo, MD, PhD|
|Description||The objective of this project is to provide a competitive clinical solution with an autologous product, a balanced cost and the possibility of extending use to other pathologies. This protocol includes treatment of 10 patients with cystic disease of the jaws that meet all the inclusion criteria and none of the exclusion criteria. For autologous cell preparation a sample of spongy bone from the maxillary tuberosity and 20 ml of serum are obtained from the patient in order to prepare the crosslinked protein matrix and the MSV-H cells. Cells are selected and expanded under GMP conditions according to the methodology used in previous trials (EudraCT 2005-005498-36, 2008-001191-68 and 2009-0170450-11 ). MSV-H cells are obtained directly from biopsy culture jawbone of the patient by cultivation techniques "in vitro" and differentiate for 21 days once conveyed in the matrix with osteogenic differentiation medium of the following composition: DMEM, 10% FBS, 1% P / E, 0.1 mM dexamethasone, 50 mM ascorbate 2-phosphate, 10 mM phosphate ßGlicerol. All differentiation factors have already been approved for clinical use. After the period of the product differentiation can be implanted to the patient. The bioimplant is used to refill the bone defects after osteotomy and maxillary cyst enucleation, with 5-10 million cells per unit of 2 cm in diameter and 0.3 cm thick. The cavity is closed with the mucoperiosteal flap and sutured with reabsorbable material. The end point of the trial is to evaluate the feasibility, safety and indications of treatment efficacy according to both clinical criteria and objective imaging confirming the volumetric bone regeneration and maintenance over time. For this purposes orthopantomography exploration will be performed before and 2 and 6 months after intervention.|
Call for more information